<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Clinical and preclinical findings</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Major effects</th>
    <th>HIV pathogen
     <sup>a</sup>
    </th>
    <th>ARV</th>
    <th>Opioids</th>
    <th>Outcome</th>
    <th>Model system</th>
    <th>Citation(s)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" colspan="7">Clinical findings (human)</td>
   </tr>
   <tr>
    <td rowspan="3">HIV progression and/or ARV adherence</td>
    <td>HIV</td>
    <td>cART</td>
    <td>
     <p>• SUD</p>
     <p>• Prescription opioids for pain</p>
    </td>
    <td>
     <p>• ↑ Viral load with SUD</p>
     <p>• ↓ ARV adherence</p>
     <p>• ↑ Frequency of prescription drugs with pain + SUD</p>
    </td>
    <td>Human</td>
    <td>(Denis et al. 
     <xref ref-type="bibr" rid="CR113">2019</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>cART</td>
    <td>OUD</td>
    <td>
     <p>• ↓ Lasting viral suppression</p>
     <p>• ↓ Adherence to cART for 3 years</p>
    </td>
    <td>Human</td>
    <td>(Lemons et al. 
     <xref ref-type="bibr" rid="CR276">2019</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>ARV naive</td>
    <td>Injection drug use</td>
    <td>↓ CD4 counts</td>
    <td>Human</td>
    <td>(Meijerink et al. 
     <xref ref-type="bibr" rid="CR332">2014</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>HIV encephalitis (HIVE)</p>
     <p>HIV infection CNS</p>
    </td>
    <td>HIV</td>
    <td>ZDV</td>
    <td>Former drug use (+ OST)</td>
    <td>
     <p>• ↑ Multinucleated giant cells</p>
     <p>• ↑ HIV p24</p>
    </td>
    <td>Human, postmortem brain</td>
    <td>(Bell et al. 
     <xref ref-type="bibr" rid="CR36">1998</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="4">Microglial activation</td>
    <td>HIV</td>
    <td>
     <p>• ARV</p>
     <p>• ZDV</p>
    </td>
    <td>OUD</td>
    <td>↑ CD68 microglial activation only in non-OUD HIV+ PWH</td>
    <td>Human, postmortem brain</td>
    <td>(Smith et al. 
     <xref ref-type="bibr" rid="CR474">2014</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>
     <p>• ARV</p>
     <p>• ZDV, other monotherapies</p>
    </td>
    <td>Injection drug use (+ OST)</td>
    <td>↑ Microglial activation</td>
    <td>Human</td>
    <td>(Bell et al. 
     <xref ref-type="bibr" rid="CR37">2002</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>No info</td>
    <td>Drug use</td>
    <td>
     <p>• ↑ MHC class II</p>
     <p>• ↑ CD68</p>
    </td>
    <td>Human, postmortem brain</td>
    <td>(Anthony et al. 
     <xref ref-type="bibr" rid="CR11">2005</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>No info</td>
    <td>OUD (44% methadone, 36% other opiates)</td>
    <td>
     <p>• ↓ CD68, HLA-D in HIV and HIVE with OUD</p>
     <p>• No effect of IDU on CD68</p>
    </td>
    <td>Human, postmortem brain</td>
    <td>(Byrd et al. 
     <xref ref-type="bibr" rid="CR68">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>Plasma cytokines</td>
    <td>HIV</td>
    <td>cART</td>
    <td>OUD (codeine, fentanyl, morphine)</td>
    <td>↑ sTNF-R2, not sCD14, TNF-α, sTNF-R1, in plasma</td>
    <td>Human</td>
    <td>(Ryan et al. 
     <xref ref-type="bibr" rid="CR444">2004</xref>)
    </td>
   </tr>
   <tr>
    <td/>
    <td>HIV</td>
    <td>ARV naive</td>
    <td>Reported heroin use</td>
    <td>
     <p>• ↓ MIP-1α, MIP-1β, MCP-2 in blood after stimulation with LPS</p>
     <p>• ↑ CCR5 expression in CD4 cells</p>
    </td>
    <td>Human</td>
    <td>(Meijerink et al. 
     <xref ref-type="bibr" rid="CR333">2015</xref>)
    </td>
   </tr>
   <tr>
    <td>HIVE</td>
    <td>HIV</td>
    <td>No info</td>
    <td>OUD</td>
    <td>
     <p>• ↑ Parenchymal inflammatory infiltrates</p>
     <p>• ↑ HIV PCR amplification products</p>
    </td>
    <td>Human, postmortem brain</td>
    <td>(Gosztonyi et al. 
     <xref ref-type="bibr" rid="CR185">1993</xref>)
    </td>
   </tr>
   <tr>
    <td>Aberrant immune responses</td>
    <td>HIV</td>
    <td>No info</td>
    <td>SUD (opioids, alcohol, marijuana, cocaine) (+ OST)</td>
    <td>
     <p>• ↑ Autoantibodies and delayed hypersensitivity to neural antigens OUD only</p>
     <p>• No HIV effect/interaction</p>
    </td>
    <td>Human</td>
    <td>(Jankovic et al. 
     <xref ref-type="bibr" rid="CR224">1991</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="3">Learning-memory</td>
    <td>HIV</td>
    <td>50-70% on cART</td>
    <td>Heroin, crack/cocaine</td>
    <td>
     <p>• ↓ Total learning; ↓ Learning slope</p>
     <p>• ↓ Delayed recall</p>
    </td>
    <td>Human, female</td>
    <td>(Meyer et al. 
     <xref ref-type="bibr" rid="CR336">2013</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>cART</td>
    <td>Reported heroin use</td>
    <td>
     <p>• ↓ Recall memory</p>
     <p>• ↓ Working memory</p>
    </td>
    <td>Human</td>
    <td>(Byrd et al. 
     <xref ref-type="bibr" rid="CR67">2011</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>No info</td>
    <td>SUD (opioids, alcohol, marijuana, cocaine)</td>
    <td>
     <p>• ↓ Complex figure copy</p>
     <p>• ↓ Delayed recall</p>
    </td>
    <td>Human</td>
    <td>(Concha et al. 
     <xref ref-type="bibr" rid="CR103">1997</xref>)
    </td>
   </tr>
   <tr>
    <td>Neuropsychological performance</td>
    <td/>
    <td>cART</td>
    <td>OST (methadone)</td>
    <td>No effect of OST</td>
    <td>Human</td>
    <td>(Applebaum et al. 
     <xref ref-type="bibr" rid="CR16">2010</xref>)
    </td>
   </tr>
   <tr>
    <td>Cognitive function</td>
    <td>HIV</td>
    <td>cART</td>
    <td>OUD</td>
    <td>• ↓ Cognitive performance with anticholinergics, but not opioids, anxiolytics, or anticonvulsants</td>
    <td>Human</td>
    <td>(Rubin et al. 
     <xref ref-type="bibr" rid="CR440">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>Memory</p>
     <p>Cognitive function</p>
    </td>
    <td>HIV</td>
    <td>cART</td>
    <td>SUD (alcohol, cocaine, heroin)</td>
    <td>
     <p>• ↓ Working memory in HIV+</p>
     <p>• ↓ Spatial and verbal response times in women, irrespective of HIV status</p>
     <p>• ↑ Response time with cocaine use</p>
    </td>
    <td>Human</td>
    <td>(Martin et al. 
     <xref ref-type="bibr" rid="CR309">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>Visual and cognitive function</td>
    <td>HIV</td>
    <td>No info</td>
    <td>OUD (+ OST, methadone)</td>
    <td>
     <p>• ↑ Pattern-shift visual evoked potential delay with methadone</p>
     <p>• No HIV effect/interaction</p>
    </td>
    <td>Human</td>
    <td>(Bauer 
     <xref ref-type="bibr" rid="CR31">1998</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="2">Transmission risk</td>
    <td>HIV</td>
    <td>No info</td>
    <td>OST</td>
    <td>↓ Frequency of injection drug use</td>
    <td>Human</td>
    <td>(Kwiatkowski and Booth 
     <xref ref-type="bibr" rid="CR265">2001</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>cART</td>
    <td>OST</td>
    <td>
     <p>• ↓ Frequency of heroin injection</p>
     <p>• ↑ On ARV</p>
    </td>
    <td>Human</td>
    <td>(Pettes et al. 
     <xref ref-type="bibr" rid="CR397">2010</xref>)
    </td>
   </tr>
   <tr>
    <td>Motor and visual function</td>
    <td>HIV</td>
    <td>No info</td>
    <td>OST</td>
    <td>
     <p>• ↓ Digital Finger-Tapping test</p>
     <p>• ↓ Visual motor pursuit</p>
    </td>
    <td>Human</td>
    <td>(Silberstein et al. 
     <xref ref-type="bibr" rid="CR467">1993</xref>)
    </td>
   </tr>
   <tr>
    <td>ARV adherence</td>
    <td>HIV</td>
    <td>cART</td>
    <td>OST</td>
    <td>• ↑ ARV adherence in PWH with OST vs. OUD</td>
    <td>Human</td>
    <td>(Mazhnaya et al. 
     <xref ref-type="bibr" rid="CR320">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <italic>PENK</italic> expression
    </td>
    <td>HIV</td>
    <td>Pre- and post-cART</td>
    <td>SUD</td>
    <td>
     <p>• ↓ 
      <italic>PENK</italic> in HIVE vs. HIV−
     </p>
     <p>• ↓ 
      <italic>DRD2L</italic> HIV+ vs. HIVE &amp; HIV−
     </p>
     <p>• ↓ 
      <italic>DRD2L</italic> correlates with 
     </p>
     <p>↑ cognitive performance</p>
    </td>
    <td>Human, post mortem brain</td>
    <td>(Gelman et al. 
     <xref ref-type="bibr" rid="CR174">2012</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="3">
     <italic>OPRM1</italic> polymorphisms, splice variants
    </td>
    <td>HIV</td>
    <td>No info</td>
    <td>SUD</td>
    <td>C17T MOR polymorphism correlates with ↑ risk of cocaine, alcohol &amp; tobacco (but not opiate) use</td>
    <td>Human</td>
    <td>(Crystal et al. 
     <xref ref-type="bibr" rid="CR107">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>cART</td>
    <td>No</td>
    <td>Some 
     <italic>OPRM1</italic> polymorphisms may alter HIV severity / response to ARV
    </td>
    <td>Human</td>
    <td>(Proudnikov et al. 
     <xref ref-type="bibr" rid="CR406">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>No info</td>
    <td>MOR-1K expression</td>
    <td>
     <p>• ↑ MOR-1K in HIVE</p>
     <p>• ↑ CCL2, CCL6, CCL5, but not CXCR4, CCR5 or CD4 receptor in HIVE</p>
    </td>
    <td>Human, postmortem brain</td>
    <td>(Dever et al. 
     <xref ref-type="bibr" rid="CR115">2014</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <italic>OPRK</italic> and 
     <italic>PDYN</italic> polymorphisms
    </td>
    <td>HIV</td>
    <td>cART</td>
    <td>No</td>
    <td>Some 
     <italic>OPRK and PDYN</italic> polymorphisms may alter HIV severity / response to ARV
    </td>
    <td>Human</td>
    <td>(Proudnikov et al. 
     <xref ref-type="bibr" rid="CR407">2013</xref>)
    </td>
   </tr>
   <tr>
    <td>Sensory Neuropathy</td>
    <td>HIV</td>
    <td>cART</td>
    <td>SUD</td>
    <td>HIV sensory neuropathy- regardless of SUD (trends, not significant)</td>
    <td>Human</td>
    <td>(Robinson-Papp et al. 
     <xref ref-type="bibr" rid="CR431">2010</xref>)
    </td>
   </tr>
   <tr>
    <td align="left" colspan="7">Preclinical in vivo findings (animal)</td>
   </tr>
   <tr>
    <td rowspan="2">HIV entry into the brain</td>
    <td>Mixture of SIV
     <sub>17-EFr</sub>, SHIV
     <sub>KU_1B,</sub> SHIV
     <sub>89.6P</sub>
    </td>
    <td>No</td>
    <td>Morphine (5 mg/kg i.m., b.i.d., ≤ 56 weeks)</td>
    <td>
     <p>• ↑ CSF viral load</p>
     <p>• ↑ Viral migration through BBB for SHIV
      <sub>KU</sub>
     </p>
    </td>
    <td>Rhesus macaques</td>
    <td>(Kumar et al. 
     <xref ref-type="bibr" rid="CR264">2006</xref>)
    </td>
   </tr>
   <tr>
    <td>SIV
     <sub>macR71/17E</sub>
    </td>
    <td>No</td>
    <td>Morphine (3 mg/kg i.m., q.i.d.)</td>
    <td>
     <p>• ↑ CD4+ and CD8+ T cells</p>
     <p>• ↑ CSF viral load</p>
     <p>• ↑ Infiltration of MDMs into the brain</p>
    </td>
    <td>Rhesus macaques</td>
    <td>(Bokhari et al. 
     <xref ref-type="bibr" rid="CR49">2011</xref>).
    </td>
   </tr>
   <tr>
    <td>Viral load and HIV progression</td>
    <td>Mixture of SIV
     <sub>17-EFr</sub>, SHIV
     <sub>KU _1B</sub>, SHIV
     <sub>89.6P</sub>
    </td>
    <td>No</td>
    <td>Morphine (5 mg/kg, i.m., t.i.d., 20 weeks)</td>
    <td>
     <p>• ↑ Viral load; ↓ CD4 counts</p>
     <p>• ↑ ROS with morphine + SIV</p>
    </td>
    <td>Rhesus macaques</td>
    <td>(Perez-Casanova et al. 
     <xref ref-type="bibr" rid="CR389">2007</xref>; Perez-Casanova et al. 
     <xref ref-type="bibr" rid="CR390">2008</xref>)
    </td>
   </tr>
   <tr>
    <td>SIV gene mutation/evolution
     <italic>tat</italic>
    </td>
    <td rowspan="4">Mixture of SIV
     <sub>17-EFr</sub>, SHIV
     <sub>KU _1B</sub>, SHIV
     <sub>89.6P</sub>
    </td>
    <td rowspan="4">No</td>
    <td rowspan="4">
     <p>Morphine</p>
     <p>(5 mg/kg, i.m., t.i.d., 20–56 weeks)</p>
    </td>
    <td>
     <p>• ↑ Viral load; ↓ CD4 counts</p>
     <p>• 
      <italic>tat</italic> evolution—inverse correlation with SIV progression
     </p>
     <p>• ↓ 
      <italic>tat</italic> diversity with morphine
     </p>
    </td>
    <td rowspan="4">Rhesus macaques</td>
    <td>(Noel and Kumar 
     <xref ref-type="bibr" rid="CR366">2006</xref>; Noel et al. 
     <xref ref-type="bibr" rid="CR369">2006b</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <italic>nef</italic>
    </td>
    <td>
     <p>• ↑ Viral load; ↓ CD4 counts</p>
     <p>• ↓ 
      <italic>nef</italic> evolution; no correlation with SIV progression ± morphine
     </p>
    </td>
    <td>(Noel et al. 
     <xref ref-type="bibr" rid="CR368">2006a</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <italic>env</italic>
    </td>
    <td>
     <p>• ↑ Viral load; ↓ CD4 counts</p>
     <p>• ↑ 
      <italic>env</italic> evolution (V4 region) correlates with SIV progression + morphine
     </p>
     <p>• ↑ 
      <italic>env</italic> evolution in CSF with morphine
     </p>
    </td>
    <td>(Rivera-Amill et al. 
     <xref ref-type="bibr" rid="CR427">2007</xref>, 
     <xref ref-type="bibr" rid="CR429">2010b</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <italic>vpr</italic>
    </td>
    <td>
     <p>• ↓ 
      <italic>vpr</italic> evolution and/or Vpr R50G mutation—inverse correlation with SIV progression/mortality
     </p>
     <p>• ↓ 
      <italic>vpr</italic> evolution with morphine
     </p>
    </td>
    <td>(Noel and Kumar 
     <xref ref-type="bibr" rid="CR367">2007</xref>; Rivera et al. 
     <xref ref-type="bibr" rid="CR426">2013</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="3">Neuronal injury, survival, oxidative stress</td>
    <td>gp120 HIV-1
     <sub>LAV</sub>
    </td>
    <td>No</td>
    <td>Morphine (25 mg pellet, 5–7 days)</td>
    <td>
     <p>• ↑ ROS during withdrawal</p>
     <p>• ↓ PSD95 during chronic and withdrawal</p>
     <p>• ↑ Sphingomyelin</p>
     <p>• ↓ Ceramide</p>
    </td>
    <td>Mouse, gp120 tg
     <sup>b</sup>
    </td>
    <td>(Bandaru et al. 
     <xref ref-type="bibr" rid="CR26">2011</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV</td>
    <td>No</td>
    <td>Morphine (37.5 mg s.c, 5 days)</td>
    <td>↓ neuron survival HIV tg + morphine</td>
    <td>Rat, HIV-1 tg, female</td>
    <td>(Guo et al. 
     <xref ref-type="bibr" rid="CR193">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>SIV</p>
     <p>HIV Tat</p>
    </td>
    <td>No</td>
    <td>Morphine (3 mg/kg i.m., q.i.d., 3 weeks)</td>
    <td>
     <p>• ↑ miR-29b, ↓ PDGF-B mRNA, ↑ PDGF-BB with morphine and SIV</p>
     <p>• ↓ PDGF-B, ↓ neuron survival with CM from morphine-treated astrocytes</p>
    </td>
    <td>Rhesus macaques; Rat
     <sup>b</sup>, primary neurons, astrocytes
    </td>
    <td>(Hu et al. 
     <xref ref-type="bibr" rid="CR213">2012</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="2">Synaptic transmission</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine ex vivo (1 μM) to the bath</td>
    <td>↓ mIPSC frequency</td>
    <td>Mouse, male and female, PFC slices, ex vivo</td>
    <td>(Xu and Fitting 
     <xref ref-type="bibr" rid="CR549">2016</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>SIV
      <sub>macR71/17E</sub>
     </p>
     <p>Tat</p>
    </td>
    <td>No info</td>
    <td>
     <p>• Morphine (escalating doses of 1–3 mg/kg i.m., q.i.d., 12 months)</p>
     <p>• Morphine in vitro</p>
    </td>
    <td>
     <p>• SIV ↑ Synaptic protein HSPA5</p>
     <p>• Tat ↑ HSPA5 mRNA (in vitro)</p>
    </td>
    <td>
     <p>Rhesus macaques;</p>
     <p>Human,</p>
     <p>SH-SY5Y neuroblastoma cells in vitro</p>
    </td>
    <td>(Pendyala et al. 
     <xref ref-type="bibr" rid="CR386">2015</xref>)
    </td>
   </tr>
   <tr>
    <td>White matter effects</td>
    <td>SIV
     <sub>macR71/17E</sub>
    </td>
    <td>No</td>
    <td>Morphine (3 mg/kg i.m., q.i.d., ≤ 59 weeks)</td>
    <td>
     <p>• ↑ Focal, demyelinating lesions</p>
     <p>• ↑ Macrophages in areas of myelin loss</p>
    </td>
    <td>Rhesus macaques</td>
    <td>(Marcario et al. 
     <xref ref-type="bibr" rid="CR306">2008</xref>),
    </td>
   </tr>
   <tr>
    <td>CNS metabolites</td>
    <td>SIV
     <sub>smm9</sub>
    </td>
    <td>No info</td>
    <td>Morphine (escalating doses of 1–3 mg/kg i.m., q.i.d., ≤ 4 years)</td>
    <td>
     <p>• ↑ Survival time</p>
     <p>• ↑ Creatine in white matter (SIV + morphine only)</p>
     <p>• ↑ Myo-inositol in putamen</p>
    </td>
    <td>Rhesus macaques</td>
    <td>(Cloak et al. 
     <xref ref-type="bibr" rid="CR100">2011</xref>)
    </td>
   </tr>
   <tr>
    <td>Neuroinflammation</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine (10 mg/kg i.p., b.i.d., 5 days)</td>
    <td>↑ Iba1+ 3-NT+ microglia</td>
    <td>Mouse, Tat tg, males</td>
    <td>(Zou et al. 
     <xref ref-type="bibr" rid="CR560">2011</xref>)
    </td>
   </tr>
   <tr>
    <td>Chemokines</td>
    <td>
     <p>Tat
      <sub>1–72</sub>
     </p>
     <p>(25 μg intrastriatal injection)</p>
    </td>
    <td>No</td>
    <td>Morphine (25 mg pellet, 5 days)</td>
    <td>
     <p>• ↑ CCL2 in astrocytes is regulated by CCR5</p>
     <p>• ↑ CCL2 in macrophages/microglia</p>
     <p>• CCL2-knockout blocks morphine + Tat-induced glial reactivity</p>
    </td>
    <td>Mouse</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR133">2008a</xref>)
    </td>
   </tr>
   <tr>
    <td>Cytokines, Chemokines</td>
    <td>HIV Tat (10 μg/kg i.v.)</td>
    <td>No</td>
    <td>Morphine (25, 75 mg pellet, 6 days)</td>
    <td>
     <p>• Morphine ↑ death in Tat + bacterial infection</p>
     <p>• ↑ TNFα, IL-6, CCL2, </p>
     <p>• ↑ TLR2, TLR4, TLR9</p>
    </td>
    <td>Mouse, male, in vivo; microglia in vitro</td>
    <td>(Dutta et al. 
     <xref ref-type="bibr" rid="CR125">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>MOR expression</td>
    <td>HIV-1
     <sub>IIIB</sub> gp120 (X4)
    </td>
    <td>No</td>
    <td>MOR</td>
    <td>↑ MOR mRNA</td>
    <td>Rats, HIV-1 tg males</td>
    <td>(Chang et al. 
     <xref ref-type="bibr" rid="CR78">2007</xref>)
    </td>
   </tr>
   <tr>
    <td>MOR-coupling efficacy to G proteins</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>
     <p>• Morphine (acute, 10 mg/kg i.p.)</p>
     <p>• Morphine, DAMGO (ex vivo)</p>
    </td>
    <td>↓ [
     <sup>35</sup>S]GTPγS binding in NAc Shell, CPu, amygdala, PFC, but not hippocampus, with morphine in Tat mice
    </td>
    <td>Mouse, Tat tg, males</td>
    <td>(Hahn et al. 
     <xref ref-type="bibr" rid="CR200">2016</xref>)
    </td>
   </tr>
   <tr>
    <td>Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine (75 mg pellet, 5 days)</td>
    <td>
     <p>• ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)</p>
     <p>• ↑ CPP and cytokines (24 h after withdrawal)</p>
     <p>• Above effects reduced by CCR5 blockade</p>
    </td>
    <td>Mouse, Tat tg, males</td>
    <td>(Gonek et al. 
     <xref ref-type="bibr" rid="CR183">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>Neuropathy</td>
    <td>gp120 (0.2 μg), q.d. intrathecally</td>
    <td>No</td>
    <td>Morphine (3 μg, intrathecally, b.i.d., 5 days)</td>
    <td>
     <p>• ↑ Mechanic allodynia</p>
     <p>• ↑ Brd4 mRNA</p>
    </td>
    <td>Rat, males, gp120</td>
    <td>(Takahashi et al. 
     <xref ref-type="bibr" rid="CR500">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>Morphine efficacy, potency</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine (acute, 2–8 mg/kg s.c.)</td>
    <td>↓ Antinociceptive potency and efficacy (tail flick)</td>
    <td>Mouse, Tat tg, males</td>
    <td>(Fitting et al. 
     <xref ref-type="bibr" rid="CR161">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>Morphine tolerance, physical dependence</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine (75 mg pellet, 4 days)</td>
    <td>
     <p>• ↑ Antinociceptive tolerance</p>
     <p>• ↓ Physical dependence</p>
    </td>
    <td>Mouse, Tat tg, males</td>
    <td>(Fitting et al. 
     <xref ref-type="bibr" rid="CR164">2016</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="3">Locomotor function</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Oxycodone (0–10 mg/kg, i.p., 15 min prior behavioral assay)</td>
    <td>↑ Locomotor activity, center entries (open field)</td>
    <td>Mouse, Tat tg, females</td>
    <td>(Salahuddin et al. 
     <xref ref-type="bibr" rid="CR446">2020</xref>)
    </td>
   </tr>
   <tr>
    <td>SIV
     <sub>macR71/17E</sub>
    </td>
    <td>No</td>
    <td>Morphine (escalating doses of 1–2.5 mg/kg i.m., q.i.d., 59 weeks)</td>
    <td>↓ Motor skill</td>
    <td>Rhesus macaques</td>
    <td>(Marcario et al. 
     <xref ref-type="bibr" rid="CR307">2016</xref>)
    </td>
   </tr>
   <tr>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Oxycodone (acute, 0.1–10 mg/kg, i.p.)</td>
    <td>↑ Psychomotor effects</td>
    <td>Mouse, Tat tg, females</td>
    <td>(Paris et al. 
     <xref ref-type="bibr" rid="CR378">2020</xref>)
    </td>
   </tr>
   <tr>
    <td>BBB integrity</td>
    <td>Tat</td>
    <td>No</td>
    <td>Morphine (25 mg pellet, 5 days)</td>
    <td>↑ Dextran extravasation across the blood-brain barrier</td>
    <td>Mouse, Tat tg females</td>
    <td>(Leibrand et al. 
     <xref ref-type="bibr" rid="CR274">2019</xref>)
    </td>
   </tr>
   <tr>
    <td>Immune cell trafficking into CNS</td>
    <td>Tat</td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ Infiltration of monocytes and T cells into 
      <italic>S. pneumoniae</italic>-infected CNS with morphine 
     </p>
     <p>• ↑ T cell CXCR4 and CCR5 expression with morphine</p>
    </td>
    <td>Mouse, CNS infection (
     <italic>S. pneumoniae)</italic>, males
    </td>
    <td>(Dutta and Roy 
     <xref ref-type="bibr" rid="CR124">2015</xref>)
    </td>
   </tr>
   <tr>
    <td>ARV accumulation</td>
    <td>Tat</td>
    <td>
     <p>DTG</p>
     <p>ABC</p>
     <p>3TC</p>
    </td>
    <td>Morphine (2 mg/day, s.c.. osmotic pump, 5 days)</td>
    <td>↓ Dolutegravir and abacavir, but no change in lamivudine in brains of morphine-treated animals</td>
    <td>Mouse, Tat tg females</td>
    <td>(Leibrand et al. 
     <xref ref-type="bibr" rid="CR274">2019</xref>)
    </td>
   </tr>
   <tr>
    <td>Circadian rhythms</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine (25 mg pellet, last 5 days)</td>
    <td>↓ Total wheel-running activity</td>
    <td>Mouse, Tat tg, males</td>
    <td>(Duncan et al. 
     <xref ref-type="bibr" rid="CR122">2008</xref>)
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <sup>a</sup>assumed Clade B, unless noted otherwise; 
   <sup>b</sup> sex not reported; 
   <sup>c</sup> authors reported a trend that was not significant
  </p>
  <p>
   <italic>ABC</italic>, abacavir; 
   <italic>ARV</italic>, antiretroviral(s); 
   <italic>BBB</italic>, blood-brain barrier; 
   <italic>b.i.d.</italic>, twice a day; 
   <italic>Brd4</italic>, Bromodomain-containing protein 4; 
   <italic>CPu</italic>, caudate-putamen; 
   <italic>CNS</italic>, central nervous system; 
   <italic>CPP</italic>, conditioned place preference; 
   <italic>CM</italic>, conditioned medium; 
   <italic>CSF</italic>, cerebrospinal fluid; 
   <italic>DAMGO</italic> [D-Ala
   <sup>2</sup>, N-MePhe
   <sup>4</sup>, Gly-ol]-enkephalin; 
   <italic>DRD2L</italic>, type 2 dopamine receptor; 
   <italic>DTG</italic>, dolutegravir; 
   <italic>HIVE</italic>, HIV encephalitis (typically seen pre-cART); 
   <italic>HSPA5</italic>, heat shock 70-kDa protein A 5; 
   <italic>IDU</italic>, injection drug use; 
   <italic>i.m</italic>., intramuscularly; 
   <italic>i.p</italic>., intraperitoneal; 
   <italic>Iba1</italic>, ionized calcium-binding adapter molecule 1; 
   <italic>3TC</italic>, lamivudine; 
   <italic>MHC class II</italic>, major histocompatibility class II; 
   <italic>mIPSC</italic>, miniature inhibitory postsynaptic currents; 
   <italic>MOR</italic>, μ-opioid receptor; 
   <italic>No info</italic>, information not provided or uncertain; 
   <italic>OST</italic>, opioid substitution therapy; 
   <italic>OUD</italic>, opioid use disorder; 
   <italic>PFC</italic>, prefrontal cortex; 
   <italic>PENK</italic>, preproenkephalin; 
   <italic>q.d</italic>., once a day; 
   <italic>q.i.d.</italic>, four times a day; 
   <italic>ROS</italic>, reactive oxygen species; 
   <italic>s.c.</italic>, subcutaneous; 
   <italic>SUD</italic>, substance use disorder; 
   <italic>tg</italic>, transgenic; 
   <italic>t.i.d</italic>., three times a day; 
   <italic>ZDV</italic>, zidovudine
  </p>
  <p>For practicality, Tables 
   <xref rid="Tab1" ref-type="table">1</xref> and 
   <xref rid="Tab2" ref-type="table">2</xref> are limited to key studies in the CNS with emphasis on neuropathological or neuroimmune rather than psychosocial outcomes. With deference toward the excellent studies we excluded: (1) on opioid and HIV effects on peripheral blood mononuclear cells (PBMCs), or on isolated lymphocytes and monocytes, not directly related to the central nervous system or BBB; (2) on HIV or opioid and ARV interactions in the peripheral nervous system; and (3) studies not directly examining opioid-HIV interactions (irrespective of whether a positive or negative interaction was found)
  </p>
 </table-wrap-foot>
</table-wrap>
